Improving Mesothelioma Therapy by Boosting Immune Responses to Mutations by Vaccination and by Immunogenic Chemotherapy
Abstract
This is the second annual report for award CA190450. The project examines neoantigen immune responses in (a) clinical samples and (b) mouse models. We have recruited 24 of the proposed 30 subjects for this study and continue to perform genomic and immunoproteomic analysis on tumour samples. Neoantigens have been bioinformatically predicted for six cases with immunological screening and analysis commenced for four. Neoantigens can be classified as simple and complex depending upon the origin of the tumour-associated alteration. In mouse studies we have experienced difficulties with analysis of complex neoantigens. In the mouse model only a restricted set of simple neoantigens induce T cell responses. To generate a protective anti-cancer vaccine we found that a combination of endogenously recognised neoantigens and a strong exogenous neoantigen is required. Vaccination with individual components is not protective. Unraveling the mechanisms underlying these differences in vaccination efficiently will be crucial to the development of neoantigen vaccines.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2022
- Accession Number
- AD1190731
Entities
People
- Alec J Redwood
- Bruce H. Robinson
- Jenette Creaney
Organizations
- University of Western Australia